|
Neoplasms
|
|
0.780 |
GeneticVariation
|
BEFREE |
The patients with BRAF K601E- and T599_V600insAGA-mutated tumors had similar clinicopathologic features to those with BRAF V600E-mutated tumors.
|
29037218 |
2017 |
|
Neoplasms
|
|
0.780 |
GeneticVariation
|
BEFREE |
We confirmed the presence of RAS mutations and BRAF K601E mutation in benign, borderline, and malignant follicular-patterned tumors.
|
29723601 |
2018 |
|
Neoplasms
|
|
0.780 |
GeneticVariation
|
BEFREE |
Cytology was consistent with "follicular neoplasia" (negative for galectin-3 immunostaining); molecular analysis on the cytology sample detected a K601E mutation in the exon 15 of the BRAF gene.
|
22136270 |
2011 |
|
Neoplasms
|
|
0.780 |
GeneticVariation
|
BEFREE |
Twenty-three percent of patients with V600E- and 43% of patients with K601E-mutant melanomas presented with nodal disease at diagnosis compared to just 14% of patients with BRAF wild-type tumors (P = 0.001 and 0.006, respectively).
|
26643848 |
2016 |
|
Neoplasms
|
|
0.780 |
GeneticVariation
|
BEFREE |
This technique, together with an earlier described real-time test specific for V600E and K601E will be useful for research and molecular diagnostic laboratories involved in the study of BRAF-related neoplasia.
|
20186005 |
2010 |
|
Neoplasms
|
|
0.780 |
GeneticVariation
|
BEFREE |
The tumor was found to be BRAF mutation positive (K601E).
|
20718682 |
2010 |
|
Neoplasms
|
|
0.780 |
GeneticVariation
|
BEFREE |
All cases positive for the BRAF(K601E) mutation were reviewed to confirm histopathologic diagnosis and establish tumor variant, and clinical charts were reviewed to obtain clinical characteristics and follow-up information.
|
26422023 |
2016 |
|
Neoplasms
|
|
0.780 |
GeneticVariation
|
BEFREE |
We describe a case of papillary thyroid carcinoma with fibromatosis/fasciitis-like stroma (PTC-FLS) that contained the rare BRAF c.1799_1801delTGA (p.V600_K601delinsE) mutation, which has not previously been reported in this tumour, as well as the CTNNB1 c.133T>C (p.S45P) mutation.
|
31327063 |
2019 |
|
melanoma
|
|
0.720 |
GeneticVariation
|
BEFREE |
Melanomas had p.V600E (n = 30), p.V600K (n = 4), p.K601E (n = 1), p.600-601delinsE (n = 1), or no p.V600 mutations (n = 31).
|
23651150 |
2014 |
|
melanoma
|
|
0.720 |
GeneticVariation
|
BEFREE |
Twenty-three percent of patients with V600E- and 43% of patients with K601E-mutant melanomas presented with nodal disease at diagnosis compared to just 14% of patients with BRAF wild-type tumors (P = 0.001 and 0.006, respectively).
|
26643848 |
2016 |
|
Thyroid Neoplasm
|
|
0.710 |
GeneticVariation
|
BEFREE |
Histopathologic and Clinical Characterization of Thyroid Tumors Carrying the BRAF(K601E) Mutation.
|
26422023 |
2016 |
|
Papillary thyroid carcinoma
|
|
0.070 |
GeneticVariation
|
BEFREE |
We describe a case of papillary thyroid carcinoma with fibromatosis/fasciitis-like stroma (PTC-FLS) that contained the rare BRAF c.1799_1801delTGA (p.V600_K601delinsE) mutation, which has not previously been reported in this tumour, as well as the CTNNB1 c.133T>C (p.S45P) mutation.
|
31327063 |
2019 |
|
Papillary thyroid carcinoma
|
|
0.070 |
GeneticVariation
|
BEFREE |
Unlike the most common BRAF mutation seen in PTC carcinoma (BRAF(V600E)), this patient's mutation was a BRAF(K601E) mutation that previously has been associated with some cases of the follicular variant of PTC.
|
22136270 |
2011 |
|
Papillary thyroid carcinoma
|
|
0.070 |
GeneticVariation
|
BEFREE |
Surprisingly, we did not identify the previously reported VK600-1E or K601E mutations in our PTC specimens.
|
17824790 |
2007 |
|
Papillary thyroid carcinoma
|
|
0.070 |
GeneticVariation
|
BEFREE |
The V599E mutation is highly prevalent in PTC with a papillary or mixed papillary follicular growth pattern, and the K600E mutation is apparently restricted to the follicular variant of PTC.
|
15095090 |
2004 |
|
Papillary thyroid carcinoma
|
|
0.070 |
GeneticVariation
|
BEFREE |
Moreover, there is a close association between the type of mutation and the PTC histotype: BRAF(V600E) is associated with conventional PTC and with histological variants of PTC displaying a prominent papillary growth pattern, whereas BRAF(K601E) is associated with the follicular variant of PTC.
|
16021577 |
2005 |
|
Papillary thyroid carcinoma
|
|
0.070 |
GeneticVariation
|
BEFREE |
Unlike BRAF(V600E), the most common mutation, K601E is strongly associated with follicular-patterned cancer, particularly with the encapsulated follicular variant of PTC, and may also be found in follicular thyroid carcinomas.
|
26422023 |
2016 |
|
Papillary thyroid carcinoma
|
|
0.070 |
GeneticVariation
|
BEFREE |
A distinct mutation in BRAF (codon K600E) was detected in three cases of the follicular variant of PTC.
|
14743508 |
2004 |
|
Follicular adenoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Twenty-seven out of 29 nodules (93%) with BRAF(K601E) mutated tumors with surgical pathology results available for review were PTC, one (3.4%) was a follicular thyroid carcinoma, and one (3.4%) was a follicular adenoma.
|
26422023 |
2016 |
|
Follicular adenoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Mutations included RAS in 20 of the 32 NIFTPs (62%), 4 of the 11 FAs (36%), and 3 of the 4 IE-PTC-FVs (75%); BRAF K601E in 1 NIFTP (3%); BRAF V600E in 5 PTC-EFGs (36%).
|
29582677 |
2018 |
|
Follicular adenoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
A distinct mutation in BRAF (codon K600E) was detected in a follicular adenoma.
|
12881714 |
2003 |
|
Follicular thyroid carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Unlike BRAF(V600E), the most common mutation, K601E is strongly associated with follicular-patterned cancer, particularly with the encapsulated follicular variant of PTC, and may also be found in follicular thyroid carcinomas.
|
26422023 |
2016 |
|
Follicular thyroid carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
The c.1801A>G mutation was identified in 4 follicular variant papillary carcinomas and one follicular carcinoma.
|
25120313 |
2014 |
|
Follicular thyroid carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
The BRAF(K601E) mutation should be included in the spectrum of genetic alterations in FTC.
|
22136270 |
2011 |
|
Secondary Neoplasm
|
|
0.020 |
GeneticVariation
|
BEFREE |
Further studies are necessary to clarify the putative clinical significance (e.g. association to blood-born metastases) of PAX8-PPARgamma rearrangement, RAS mutations, and BRAF(K601E) in FVPTCs.
|
16219715 |
2006 |